Along with AS, secukinumab can ghd australia interest level be in clinical trials for that therapy for psoriatic arthritis (PsA) and arthritis (RA). US regulatory applications for secukinumab in AS and PsA are planned for 2015. This follows the secukinumab US regulatory application for ghd australia 5th us cavalry moderate to severe plaque psoriasis that is filed in October 2013 with approval anticipated at the begining of 2015..